



US009510941B2

(12) **United States Patent**
Bishop et al.

(10) **Patent No.:** **US 9,510,941 B2**

(45) **Date of Patent:** ***Dec. 6, 2016**

(54) **METHOD OF TREATING A PATIENT USING A RETRIEVABLE TRANSCATHETER PROSTHETIC HEART VALVE**

(75) Inventors: **Gordon B. Bishop**, Santa Rosa, CA (US); **Randall T. Lashinski**, Santa Rosa, CA (US)

(73) Assignee: **DIRECT FLOW MEDICAL, INC.**, Santa Rosa, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1320 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/069,209**

(22) Filed: **Mar. 22, 2011**

(65) **Prior Publication Data**

US 2011/0213460 A1 Sep. 1, 2011

Related U.S. Application Data

(63) Continuation of application No. 11/579,723, filed as application No. PCT/US2005/015617 on May 5, 2005, now Pat. No. 8,377,118.

(60) Provisional application No. 60/568,402, filed on May
(Continued)

(51) **Int. Cl.**
A61F 2/24 (2006.01)
A61B 17/064 (2006.01)
(Continued)

(52) **U.S. Cl.**
CPC **A61F 2/2409** (2013.01); **A61B 17/068** (2013.01); **A61B 17/0644** (2013.01);
(Continued)

(58) **Field of Classification Search**
CPC A61F 2/24; A61F 2/2409; A61F 2/2418; A61F 2/2427; A61F 2/2439; A61F 2250/0069; A61F 2250/0003
USPC 623/1.25, 2.14, 2.18, 2.42
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,751,911 A 6/1956 Held
3,416,562 A 12/1968 Freeman et al.

(Continued)

FOREIGN PATENT DOCUMENTS

DE 2700531 C2 4/1985
JP 10-507097 7/1995

(Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 09/496,231, Jeffrey A. Hubbell et al., Biomaterials Formed by Nucleophilic Addition Reaction to Conjugated Unsaturated Groups, filed Feb. 1, 2000.

(Continued)

Primary Examiner — David Isabella

Assistant Examiner — Suba Ganesan

(74) *Attorney, Agent, or Firm* — Morgan, Lewis & Bockius LLP

(57) **ABSTRACT**

An implantable prosthetic valve has an in situ formable support structure. The valve comprises a prosthetic valve, having a base and at least one flow occluder. A first flexible component is incapable of retaining the valve at a functional site in the arterial vasculature. The first component extends proximally of the base of the valve. A second flexible component is incapable of retaining the valve at a functional site in the arterial vasculature. The second component extends distally of the base of the valve. At least one rigidity component combines with at least one of the first and second flexible components to impart sufficient rigidity to the first or second components to retain the valve at the site.

41 Claims, 98 Drawing Sheets

